BTK and B-cell chronic lymphocytic leukemia: Notably, the BTK inhibitor Ibrutinib has emerged in recent years as a very promising drug in B-CLL treatment, although few patients show mechanisms of resistance due to C481S mutation of BTK sequence preventing the irreversible binding of Ibrutinib to BTK.